52 results about "Tyrosine Kinase 3" patented technology

The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.

Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and / or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor / stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.

The invention relates to a compound for inhibiting the activity of BTK (Bruton's Tyrosine Kinase) and / or JAK3 (Janus Tyrosine Kinase 3), a medicinal composition of the compound, a use of the compound in the pharmacy, a method for inhibiting the activity of BTK and / or JAK3 by using the compound, and a method for treating and / or preventing BTK and / or JAK3 mediated diseases or illnesses in mammals (especially human beings) by using the compound. The compound is represented by structural formula I shown in the specification.

There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.

The invention discloses a culture system for the amplification of hematopoietic stem cells of cord blood and applications thereof. The culture system contains a 1640 culture medium, fetal bovine serum (FBS), thrombopoietin, stem cell factor (SCF) and human FMS tyrosine kinase 3 ligand Flt-3L and also contains pleiotrophin PTN. A proper concentration of PTN is added in the existing hematopoietic stem cell medium to prepare the culture system which can support the growth and amplification of the hematopoietic stem cells of cord blood more effectively in vitro and particularly increase the implanting capability of hematopoietic stem cells after being implanted in a receptor obviously and the reconstruction capability of the hematopoietic system. Therefore, new application prospects are opened up for the clinical applications of the stem cells of cord blood.

The invention belongs to the technical field of organic synthetic medicines, and particularly relates to a substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative, and a preparation methodand use thereof. The substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative has a structural formula shown in Formula I. The invention also provides the preparation method of the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative and use of the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative in preparation of FMS-tyrosine kinase 3 inhibitors. A new and effective choice is provided for the preparation of the kinase inhibitors, the preparation of drugs for anti-autoimmune diseases, the preparation of neovascularization inhibitors and anti-tumordrugs in the field, and the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative has a good application prospect.

The invention relates to a stem cell amplifying culture medium and a stem cell culture method. The ingredients of the stem cell amplifying culture medium comprise a basic culture medium, a stem cell factor, thrombopoietin, an FMS like tyrosine kinase 3 ligand and interleukin-6, wherein the final concentration of the stem cell factor is 90ng / mL-110ng / mL, the final concentration of the thrombopoietin is 10ng / mL-30ng / mL, the final concentration of the FMS like tyrosine kinase 3 ligand is 90ng / mL-110ng / mL, and the final concentration of the interleukin-6 is 10ng / mL-30ng / mL. When the stem cell amplifying culture medium is used for culturing cord blood hematopoietic stem cells, obvious cell amplifying effects can be presented, CD34+ on cell surfaces is also notably increased, during cell amplification, the cell state is stable, the multi-directional differentiation capacity is maintained, and the culture medium is an economic efficient culture system.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

Disclosed herein are methods and compositions related to the treatment, prevention, and / or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates tothe use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA[delta]C7L and VACV[delta]C7L, respectively),alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA[delta]C7L or VACV[delta]C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte / macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 ligand and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.

The invention relates to the field of medicinal chemistry, discloses an indole substituted azole compound and applications thereof, and specifically relates to an indole substituted azole compound anda preparation method thereof, a pharmaceutical composition containing the indole substituted azole compound, and medical applications of the indole substituted azole compound and the pharmaceutical composition, especially applications as FMS-like tyrosine kinase 3 inhibitors.

The invention relates to the field of medicinal chemistry, and discloses a benzimidazole substituted azole compound and applications thereof, and specifically relates to a benzimidazole substituted azole compound and a preparation method thereof, a pharmaceutical composition containing the benzimidazole substituted azole compound, medical applications of the benzimidazole substituted azole compound and the pharmaceutical composition, and especially applications as FMS-like tyrosine kinase 3 inhibitors.

The invention belongs to the field of detection, and particularly relates to a serum-free medium capable of amplifying mesenchymal stem cells and a preparation method thereof. The serum-free medium mainly contains curcumin, cepharanthine, berberine, resveratrol, anthocyanidin, bone morphological protein 4, beta-glycerophosphate, cholesterol, isobutyl methyl xanthine, EGF, biotin, aFGF, heparin sodium, reduced glutathione, transferrin, insulin, ascorbic acid, dexamethasone, interleukin 2, vitamin B12, interleukin 6, stem cell factors, nicotinamide, TGF-beta 3, thrombopoietin, taurine, rosiglitazone, FMS-like tyrosine kinase 3 ligand, IGF2, sodium pyruvate, GM-CSF, TPO and the like. The serum-free culture medium not only has the capacity of amplifying mesenchymal stem cells derived from fat, placenta, bone marrow and umbilical cord in vitro, but also can maintain self-renewal of the stem cells, prevent differentiation of the stem cells and inhibit canceration of the stem cells.

The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.

The invention belongs to the field of traditional Chinese medicine detection and particularly relates to a serum-free culture medium capable of proliferating hematopoietic stem cells and a preparationmethod of the culture medium. The provided serum-free culture medium capable of proliferating hematopoietic stem cells comprises stephanine, berberine, bFGF, aFGF, IGF1, IGF2, transferrin, insulin growth factors, EGF, interleukin 1, interleukin 2, interleukin 6, stem cell factors, thrombopoietin, fMS-like tyrosine kinase 3 ligands and a DMEM / F12 culture medium. By adding stephanine and berberine,the serum-free culture medium not only has the capability of proliferating the hematopoietic stem cells derived from placentae, bone marrow and peripheral blood in vitro, improving the adherence capability of the hematopoietic stem cells and increasing the cell proliferation rate of the hematopoietic stem cells but also can maintain the self-renewal capability and multidirectional differentiationcapability of the stem cells. The hematopoietic stem cells proliferated by the serum-free culture medium have a good effect of promoting the reconstruction of a hematopoietic system in the body of apatient.

The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineeredimmune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).

FMS-like tyrosine kinase 3L (FLT3L) fused to human cytokines, which find use in, e.g., cancer treatments, is described. Accordingly, in some aspects, the present invention relates to a chimeric protein comprising a targeting moiety which comprises a single copy of FMS-like tyrosine kinase 3 ligand (FLT3L), or a portion thereof. In various embodiments, the targeting moiety functionally modulates the antigen or receptor of interest. In some embodiments, the targeting moiety binds but does not functionally modulate the antigen or receptor of interest.

The present invention discloses a culture system used for umbilical cord blood hematopoiesis stem cell amplification and application thereof, the culture system includes an AIM-V culture medium, platelet lysate PL, stem cell factor SCF, human FMS-like tyrosine kinase 3 ligand Flt-3L , G-CSF and IL-3, and angiopoietin-likeprotein 3 (ANGPTL3), small molecule compound StemRegenin (SR1) and pyrimidine-indole molecule UM171 are also added. By adding of the appropriate concentration of ANGPTL3, SR1 and UM171 for combination, the number of hematopoiesis stem cell population is greatly increased, the culture system is used for umbilical cord blood hematopoiesis stem cell growth and amplification, to be more important, implantation capacity and hematopoietic system reconstruction capacity after hematopoietic stem cells are transplanted into a receptor are significantly improved, and the culture system opens up new use prospects in clinical amplification of umbilical cord blood stem cells.

The present invention provides novel human fins related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and / or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3×CD3 antibody format and show excellent target affinity and / or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.

The invention discloses a 3D model for culturing hematopoietic stem cells by simulating the bone marrow environment as well as a preparation method and application of the 3D model. The 3D model comprises a cell culture medium and a collagen solution, wherein the cell culture medium comprises 1% (v / v) of a penicillin / streptomycin serum-free stem cell basal culture medium, 100 ng / mL of a recombinanthuman stem cell factor, 50 ng / mL of recombinant human thrombopoietin, 50 ng / mL of recombinant human FMS-like tyrosine kinase 3 and 50 ng / mL of interleukin-3. Compared with the prior art, the 3D modelhas the following advantages that (1) the 3D model firstly adds cells into collagen to promote cell polymerization, thereby simulating the environment of hematopoietic stem cells in extracellular matrix to the greatest extent; (2) the cell culture medium is subsequently added into the collagen containing stem cells by the 3D model, so that the collagen can well permeate to provide nutrition for cell proliferation; and (3) the 3D model reserves the multidirectional differentiation capability of the hematopoietic stem cells, so that a good application prospect is provided for in-vitro expansionof the hematopoietic stem cells.

An in vitro culture method for inducing human umbilical cord blood cells CD34+ to differentiate into Langerhans cell includes culturing human umbilical cord blood cells CD34+ in a medium containing GM-CSF (granulocyte-macrophage colony stimulating factor), TNF-alpha (tumor necrosis factor-alpha), SCF (stem cell factor) and Flt3L (FMS-like tyrosine kinase 3 ligand), and differentiating the human umbilical cord blood cells CD34+ into Langerhans cells. The Langerhans cells generated are highly pure and high in yield, and have the functions of recognizing, absorbing and processing antigens and the function of activating immune response.

The invention relates to the field of medicinal chemistry, and discloses an oxygen-containing heterocyclic substituted azole compound and applications thereof, and specifically relates to an oxygen-containing heterocyclic substituted azole compound and a preparation method thereof, a pharmaceutical composition containing the oxygen-containing heterocyclic substituted azole compound, and medical applications of the oxygen-containing heterocyclic substituted azole compound and the pharmaceutical composition, particularly applications as FMS-like tyrosine kinase 3 inhibitors.